Inovio Pharmaceuticals, Inc. cash flow to debt ratio of -946.10% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Inovio Pharmaceuticals, Inc.'s free cash flow has increased -14.97% from $-104.56M last year to $-88.92M, signaling increasing performance

Inovio Pharmaceuticals, Inc.'s debt to equity ratio is 1.43, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Inovio Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.17 last year to 1.43 today, signaling weakened financials

Inovio Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Inovio Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Inovio Pharmaceuticals, Inc.'s profit margin has increased (-100.00%) in the last year from -49.25K% to 0.00%, signaling increasing performance

Inovio Pharmaceuticals, Inc.'s short-term assets of $61.12M exceed its short-term liabilities of $43.67M

Inovio Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Inovio Pharmaceuticals, Inc.'s return on equity of -666.47%, is lower than 15.00%, indicating bad performance

Inovio Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Inovio Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Inovio Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Inovio Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Inovio Pharmaceuticals, Inc.'s yearly earnings has increased -20.80% since last year from $-107.25M to $-84.95M, signaling increasing performance

Inovio Pharmaceuticals, Inc.'s yearly revenue has decreased -69.99% since last year from $217.76K to $65.34K, signaling decreasing performance

ROIC -567.11% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Inovio Pharmaceuticals, Inc.'s 3-year revenue CAGR of -81.47% is negative, indicating declining revenue over the past 3 years

Inovio Pharmaceuticals, Inc. had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance

Inovio Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Inovio Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Inovio Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Inovio Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Inovio Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Inovio Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Inovio Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Inovio Pharmaceuticals, Inc. has a price-to-book ratio of 125.27x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Inovio Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue